Abstract
DSM will invest $25 million in the biobased chemicals maker Amyris and may follow with another $25 million. At the same time, the two firms will work on health-related products. They have an exclusive agreement to develop a fermentation route to vitamin A, which is normally made via chemical synthesis. If DSM does invest the full $50 million, it will own almost one-quarter of Amyris. Other, unnamed investors have committed an additional $45 million. Amyris will use most of the funds to pay down debt.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
